is

an expert in this space.

She's kind of led global business development for the likes of Thermo and others in the space.

And actually in her former company, which was a company called Trilink, they were one of the first CDMOs to test our product back in the day.

So they actually had like a physical testing and evaluation, successful testing and evaluation of our technology.

And we were able to co-market that a little bit.

So we were able to attract her and some of that other team on the basis that we had already proven that technology works very well.

What's getting you all excited about the next five years? What can we look forward to?

Related to the products that you sell, what are some of the challenges or limitations in the field right now?

That's a great question.

And maybe I should have started with this.

Corby's Bio manufactures DNA, but we manufacture it incredibly uniquely in that we use enzymes.

And essentially, the objective there is to displace an incumbent technology, which is a technology called plasma DNA.

Plasma DNA is derived from bacterial fermentation, so it's grown in bugs, in E. coli.

And as such, there are a lot of limitations associated with that manufacturing process.

Could you maybe go into a bit more detail on synthetic DNA amplification technology?

I'd now like to hand you over to Amy Walker, CEO.

Thank you very much.

So I'd like to start off today with ForBaseBio's mission statement, and that's really through our enzymatically produced DNA, we enable clinical and commercial biomanufacturing for advanced therapeutics, empowering safer, faster, more cost-effective treatments to improve outcomes for patients worldwide.

I'd also like to take the opportunity to introduce the new leadership team here at 4BaseBio.

So people might remember me.

My name is Amy Walker.

I'm the Chief Executive Officer and I was appointed as CEO in February of this year, formerly serving as Chief Operating Officer.

And I'll pick up from you at the end.

For investors who don't know 4BaseBio yet, what problem does synthetic DNA solve that plasma DNA can't? And why is that shift gaining momentum now?

Thank you, Stephen.

I think by definition, Warbase Bio is a company that makes DNA.

And the way that we make DNA is fairly unique because instead of using conventional fermentation that is typical of plasmid production, we actually use enzymes to amplify our DNA.

And so what this means is a much cleaner process.

safer, cost-effective, and faster type of DNA that we can deliver to our partners, be that biopharma, be that biotech companies, or be that some of our CDMO partners.

I think with respect to where we can feed that DNA into, really DNA is used as a building block in all of cell and gene therapy and more broadly in vaccine applications and gene editing applications.

How do these fit into the commercial growth strategy you're driving forward, Amy?